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structures vary by IOP threshold values. Day-time IOP control
with PGAs is associated with night-time IOP control whatever
the IOP threshold.
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OBJECTIVES: To conﬁrm, in everyday practice, results from
randomized clinical trials indicating that DuoTrav (a ﬁxed tra-
voprost and timolol combination) controls intra-ocular pressure
(IOP) better than Xalacom (a ﬁxed latanoprost and timolol com-
bination), even when measured >24 hours after last instillation.
METHODS: Patients with ocular hypertension or primary open
angle glaucoma and treated by one of the above combinations
were included in this cross-sectional study. Demographics,
medical history and previous treatments were abstracted from
medical records. IOP and treatment time were collected during
an ofﬁce visit. Analyses of variance, logistic regressions and pro-
pensity scores were used to adjust for confounding factors.
RESULTS: In total, 328 patients were included, 127 treated with
DuoTrav and 201 with Xalacom. The mean age was 64.6 years
and 51.5% were female. Most (275: 84.6%) had last instilled
treatment the previous day. Treatment groups were comparable
except that Xalacom-treated patients had longer disease and
treatment durations. Overall mean IOPs were 24.9 mmHg at
diagnosis and 21.1 mmHg upon starting the ﬁxed combination
treatment. There was no signiﬁcant difference between the groups
as they started their second line therapy. Duotrav-treated patients
experienced better IOP control (17.1 versus 19.1 mmHg:
p < 0.001). A difference was also noted for patients who missed
their last scheduled treatment (17.2 versus 20.1 mmHg:
p < 0.006). Better IOP control with DuoTrav was further sup-
ported by patients whose last instillation was 9.00–12.00 hours
before IOP measurement (16.5 versus 19.3 mmHg; p < 0.001).
According to the practitioners, 83.1% of the DuoTrav-treated
patients attained their IOP targets, as compared to 51.3% of
Xalacom-treated patients (p < 0.001). All these differences per-
sisted after adjustment for confounding factors. CONCLUSION:
This everyday practice study paralled the published correspond-
ing prostaglandin results of Topouzis and DuBiner, i.e. compared
to Xalacom, IOP control with DuoTrav is better and has a longer
residual effect when measured >24 hours later.
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OBJECTIVES: The rationale for this study was to provide data
for the German health care system in order to investigate the
assumption that ranibizumab is a cost-effective option for the
treatment of neovascular AMD. METHODS: We modeled cost-
effectiveness for ranibizumab-treatment of the patient’s “better”
eye based on the development of visual acuity in our phase III
studies (ANCHOR/MARINA) compared to a control group who
received best supportive care (e.g. visual aids, regular check-ups).
In the base-case, we computed 6 treatments per year for 2 years
and used the same patient entry age (77 years) and distribution of
visual acuity of the model population as in our phase III studies.
Utility values came from a study by Brazier et al. Costs and
beneﬁts were discounted annually at 5%. Costs of drugs and
treatment procedures were determined based on German phar-
macy retail prices, the German code book for physicians’ fees
(EBM 2000plus) and German DRGs. We conducted a sensitivity
analysis in order to test the stability of our model assumptions.
Variations of the base-case scenario included e.g. patient age:
50–85 years, visual acuity at start of therapy: btw. > 4.0 and
0.05–0.1 or duration of therapy: 1–3 years. RESULTS: The base-
case scenario yielded the following costs per QALY: 16.882 € for
predominantly classic lesions, 24.766 € for minimally classic
chorioidal neovascularization (CNV) and 26.170 € for occult
CNV. When weighing the costs per QALY according to the
distribution of these lesion types (18%–25%–57%), the mean
costs per QALY for the therapy of wet AMD with ranibizumab
amount to 24.147 €. The treatment was cost-effective even under
adverse conditions, e.g. longer treatment duration, high visual
acuity at start of treatment, high patient age, increased costs per
injection. CONCLUSION: Therapy of neovascular AMD with
ranibizumab is cost-effective for all angiographic subtypes
assuming a realistic variation of model parameters.
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OBJECTIVES: Ganfort is a ﬁxed combination product contain-
ing bimatoprost 0.03% and timolol 0.5% indicated for lowering
IOP of patients with glaucoma or ocular hypertension. Other
ﬁxed combination products such as Xalacom (latanoprost
0.005% and timolol 0.5%) and Duotrav (travoprost 0.004%and
timolol 0.5%) are also available on the market. All products have
the advantage of being more convenient for the patient due to
once-daily administration. Since no head to head studies
compare the three combination products, an indirect comparison
is used based on available clinical data. The purpose was to
investigate the cost-effectiveness of the three ﬁxed combination
therapies in eight European countries. METHODS: A systematic
literature search was conducted in order to identify randomized
clinical trials of Duotrav and Xalacom. Studies were selected
which had reduction in IOP as primary endpoint and which were
comparable with data from randomized controlled trials of
Ganfort with respect to study design, diagnosis and patient popu-
lation, so that an indirect comparison could be conducted. A
decision analytic cost-effectiveness model was constructed. The
cost evaluated was cost of medication and clinical visits to an
ophthalmologist. All drug costs are market prices inclusive of
VAT and visit costs are priced using ofﬁcial tariffs. Patients
discontinuing treatment due to adverse events were assumed to
change therapy and had an extra clinical visit. RESULTS: The
cost-effectiveness analysis showed that the cost per percentage
reduction in IOP was least costly for Ganfort. By using Ganfort
therapy, savings per percentage reduction in IOP ranged from
€0.06 to €0.22 compared to Duotrav and €0.02 to €0.36 com-
pared to Xalacom. CONCLUSION: This analysis concludes that
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